Market Overview

ProQR Therapeutics Has Limited Downside Or Upside According to Chardan

Share:

Shares of ProQR Therapeutics NV (NASDAQ: PRQR) have lost 48.2 percent year-to-date. Chardan Capital Markets’ Madhu Kumar initiated coverage of the company with a Neutral rating and a price target of $4.50. The analyst commented that following the underperformance, ProQR’s shares have limited downside potential, while upside potential is limited as well due to competition.

Clinical Catalysts Meet Competition

ProQR’s lead asset, QR-010, is currently in phase Ib/II clinical development and data is expected in mid/late-2016. “We particularly highlight competition from unrated Vertex, Nivalis, and Proteostasis, which have preclinical data as good as or superior to QR-010 and/or are significantly more advanced clinically,” analyst Madhu Kumar wrote.

Although there are concerns related to ProQR’s competitive position, shares have underperformed year-to-date, down 48.2 percent as of June 14, 2016, versus a 22.4 percent decline in the SPDR S&P Biotech ETF. Kumar believes that the “risk/reward dynamics are balanced ahead of upcoming clinical catalysts.”

“We assume a 25% probability of success (POS) for QR-010 (NPV €0.30/share). We value ProQR’s other pipeline programs at a NPV of €0.02/share, yielding an equity value per share of €3.98,” the analyst added.

Latest Ratings for PRQR

DateFirmActionFromTo
Nov 2019CitiMaintainsBuy
Nov 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Sep 2018Evercore ISI GroupInitiates Coverage OnOutperform

View More Analyst Ratings for PRQR
View the Latest Analyst Ratings

 

Related Articles (PRQR)

View Comments and Join the Discussion!

Posted-In: Chardan Capital Markets Madhu KumarAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
WLKCFRADowngrades37.0
KMXCFRAMaintains75.0
KIDSNeedhamMaintains46.0
LKNeedhamSuspends40.0
BSXNeedhamMaintains43.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com